XOMA's Gevokizumab Wins FDA Orphan Drug Designation

XOMA Corporation announced that the U.S. Food and Drug Administration has granted orphan drug designation to its IL-1 beta modulating antibody labeled gevokizumab for the treatment of pyoderma gangrenosum.

http://ift.tt/1hUQeLd